Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC. (Q37209537)

19 August 2017

1 reference

title

Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC. (English)

1 reference

19 August 2017

Robert A Figlin

1

1 reference

19 August 2017

publication date

8 July 2008

1 reference

Nature Clinical Practice Oncology

19 August 2017

published in

1 reference

19 August 2017

volume

5

1 reference

19 August 2017

issue

10

1 reference

19 August 2017

page(s)

601-609

1 reference

Rapamycin for immunosuppression in organ allografting.

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

A mammalian protein targeted by G1-arresting rapamycin-receptor complex

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Role of VHL gene mutation in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Recent progress in the management of advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Targeting von Hippel-Lindau pathway in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Opposite translational control of GLUT1 and GLUT4 glucose transporter mRNAs in response to insulin. Role of mammalian target of rapamycin, protein kinase b, and phosphatidylinositol 3-kinase in GLUT1 mRNA translation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: A crossroad between cancer and diabetes?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Predicted mechanisms of resistance to mTOR inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1173

7 January 2021

Identifiers

DOI

10.1038/NCPONC1173

1 reference

19 August 2017

1 reference